AnaptysBio Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About ANAB
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Find out what a historical investment in AnaptysBio Inc would be worth today using our ANAB stock calculator.
$1.69B
-
0.00%
774.61K
$70.22
$59.29
$59.89
$60.60
$11.40
Ready to start your investing journey with Stake?
Open an accountANAB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ANAB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ANAB
on Stake
Buy ANAB from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of ANAB from only US$10 with fractional shares
